Scarica l'app Stockscreener
1.22
10.29%
-0.14
Dopo l'orario di chiusura:
1.22
Precedente Chiudi:
$1.36
Aprire:
$1.34
Volume 24 ore:
169.08K
Relative Volume:
0.27
Capitalizzazione di mercato:
$60.78M
Reddito:
$96.63M
Utile/perdita netta:
$-63.32M
Rapporto P/E:
-0.8356
EPS:
-1.46
Flusso di cassa netto:
$-54.55M
1 W Prestazione:
-18.12%
1M Prestazione:
-21.29%
6M Prestazione:
-52.25%
1 anno Prestazione:
-71.82%
Intervallo 1D:
$1.22
$1.34
Intervallo di 1 settimana:
$1.22
$1.49
Portata 52W:
$1.22
$4.65
Akoya Biosciences Inc Stock (AKYA) Company Profile
Nome
Akoya Biosciences Inc
Settore
Industria
Telefono
855.896.8401
Indirizzo
100 CAMPUS DRIVE, MARLBOROUGH
Confronta AKYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.22 | 60.78M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
494.61 | 177.21B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
221.59 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
89.61 | 44.32B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
213.35 | 31.33B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
31.35 | 16.08B | 17.28B | 108.00M | 391.00M | 0.20 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Downgrade | Craig Hallum | Buy → Hold |
| 2024-08-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-02-02 | Iniziato | UBS | Buy |
| 2022-11-03 | Iniziato | CapitalOne | Overweight |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-06-22 | Iniziato | BTIG Research | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-05-11 | Iniziato | Canaccord Genuity | Buy |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Akoya Biosciences Inc Borsa (AKYA) Ultime notizie
Akoya Biosciences and Team SAMBAI Announce Selection of the - GlobeNewswire
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion For Cancer Equity Research - Nasdaq
Major Breakthrough: Akoya Wins $25M Cancer Study to Address Global Health Disparities - Stock Titan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 30.8% in March - Defense World
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - MarketScreener
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
Tikvah to oppose Quanterix-Akoya Biosciences merger By Investing.com - Investing.com Australia
Tikvah to oppose Quanterix-Akoya Biosciences merger - Investing.com India
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - Business Wire
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Marketscreener.com
Key Investor Fights Back: Quanterix Merger Under Fire Over Valuation Concerns - Stock Titan
Akoya Biosciences (AKYA) to Release Quarterly Earnings on Monday - Defense World
Akoya Biosciences Reports 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Akoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from Stephens - Defense World
Akoya Biosciences Shares Down 6.4% After Stock Offering… -June 08, 2023 at 10:10 am EDT - Marketscreener.com
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges - Investing.com Australia
Akoya: Q4 Earnings Snapshot - Milford Mirror
Akoya Biosciences earnings missed by $0.01, revenue topped estimates - Investing.com Australia
Akoya Biosciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Akoya Biosciences, Inc. SEC 10-K Report - TradingView
Kent Lake urges Quanterix to address questions regarding Akoya deal -March 17, 2025 at 04:28 pm EDT - Marketscreener.com
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Amid Pending Acquisition by Quanterix Corporation - Nasdaq
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results - GlobeNewswire
Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity - Stock Titan
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger -March 11, 2025 at 10:40 am EDT - Marketscreener.com
Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns - StockTitan
Akoya climbs after merger deal with Quanterix - MSN
Piper Sandler Downgrades Akoya Biosciences to Neutral From Overweight, Adjusts Price Target to $2.40 From $3 - Marketscreener.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral - Investing.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral By Investing.com - Investing.com Canada
Quanterix Announces Acquisition of Akoya Biosciences - TipRanks
Quanterix Highlights Benefits Of Akoya Biosciences Acquisition -March 03, 2025 at 06:13 am EST - Marketscreener.com
Can Quanterix's Akoya Acquisition Transform Biomarker Detection and Deliver $1B Revenue? - StockTitan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 60.1% in February - Defense World
Akoya Biosciences (AKYA) to Release Earnings on Monday - MarketBeat
Akoya Biosciences’ Merger with Quanterix Moves Forward - Investing.com India
Quanterix advances towards Akoya Biosciences acquisition By Investing.com - Investing.com Australia
Akoya Biosciences' Merger with Quanterix Moves Forward By Investing.com - Investing.com South Africa
Quanterix advances towards Akoya Biosciences acquisition - Investing.com
Akoya Biosciences’ Merger with Quanterix Moves Forward By Investing.com - Investing.com UK
Akoya Biosciences Inc Azioni (AKYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.94%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):